Loading
Cancer Cells and Metastasis / Breast Cancer Treatment Studies · Journal article
Frontiers in Oncology · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a hypothesis-driven conceptual framework proposing that no evidence of disease (NED) should be pursued as a distinct clinical goal in carefully selected metastatic breast cancer patients, integrated through systemic therapy, tumor immune microenvironment remodeling, and metastasis-directed therapy. The article introduces a Clinical NED Score, TIME-modifiability assessment, and a five-step algorithm, but presents no empirical validation, trial data, or clinical outcomes to support these proposals.
Journal article. Selected patients with metastatic breast cancer deemed suitable candidates for NED-oriented approach.
NED is proposed as a distinct clinical state separate from radiological complete response, defined by systemic disease control, tumor immune microenvironment remodeling, and local eradication of visible lesions ADCs are hypothesized as potential tumor-ecosystem engineering tools with effects extending beyond cytotoxicity to include bystander killing, immunogenic cell death, and immune reconfiguration Five proposed endpoints for evaluating NED include NED interval, polymetastatic progression-free survival, systemic therapy switch-free survival, ctDNA-negative duration, and quality-of-life preservation
ADCs are hypothesized as potential tumor-ecosystem engineering tools with effects extending beyond cytotoxicity to include bystander killing, immunogenic cell death, and immune reconfiguration
This framework is intended as a testable hypothesis for future research and does not yet provide evidence-based guidance for clinical practice. It represents a conceptual reorganization of treatment goals that requires prospective validation before clinical implementation.
This is a conceptual framework and theory article proposing a testable hypothesis about NED-oriented oncology in metastatic breast cancer, without presenting empirical data or clinical trial results to validate the approach.
This framework is intended as a testable hypothesis for future research and does not yet provide evidence-based guidance for clinical practice. It represents a conceptual reorganization of treatment goals that requires prospective validation before clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metastatic breast cancer (MBC) has traditionally been managed as an incurable systemic disease in which the main goals are survival extension, symptom control, and preservation of quality of life. This principle remains appropriate for most patients. However, contemporary systemic therapies, high-resolution imaging, antibody-drug conjugates (ADCs), immune checkpoint inhibition, liquid biopsy, and metastasis-directed therapy (MDT) have made prolonged no evidence of disease (NED) clinically recognizable in selected patients. This Hypothesis and Theory article proposes NED-oriented oncology as a testable framework for carefully selected patients with MBC. The central premise is that complete response and NED should be separated conceptually: complete response is a radiological treatment-response category, whereas NED is a clinical state produced by the integration of systemic disease control, biological remodeling of the tumor immune microenvironment (TIME), and local eradication of all residual visible lesions. We propose a Clinical NED Score to structure candidate selection, a TIME-modifiability layer to estimate biological convertibility, and a five-step algorithm in which systemic therapy is used to generate deep response and immune-ecological remodeling before MDT is considered at maximal response. ADCs are discussed as potential tumor-ecosystem engineering tools because their effects may extend beyond direct cytotoxicity to bystander killing, immunogenic cell death, antigen release, and immune reconfiguration. This framework does not imply that MBC is broadly curable. Rather, it argues that durable NED is a clinically meaningful, prospectively testable state that should be distinguished from transient radiological response and evaluated using endpoints such as NED interval, polymetastatic progression-free survival, systemic therapy switch-free survival, ctDNA-negative duration, and quality-of-life preservation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.